Navigation Links
MedClean Technologies Inc. CEO Publishes Letter to Shareholders
Date:2/12/2009

President and CEO, Scott Grisanti, Publishes Letter Outlining Strategy, Market Opportunity and New Leadership Team

BETHEL, Conn., Feb. 12 /PRNewswire-FirstCall/ -- MedClean Technologies, Inc. (OTC Bulletin Board: MCLN), a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste, today announced that its President and CEO, Scott Grisanti, has published a letter to shareholders. The letter, which is available on the Company's website at www.medcleantechnologies.com, outlines MedClean's new strategy, the expanded, $2 billion annual opportunity for the Company's technology and expertise, its go-to-market strategy and the new leadership team in place to execute the strategic plan.

Mr. Grisanti commented, "The letter published today and mailed to shareholders discusses the Company's strategy, which is designed to achieve a break-out position in the rapidly growing industry of regulated medical waste processing. The annual market for regulated medical waste treatment and processing is $2 billion in the U.S. alone and MedClean possesses innovative technologies and provides unique solutions to meet the specific needs of the various segments of this market. The fundamentals of our strategic plan can be boiled down to three things: leadership, product and sales, and this letter addresses each of these topics. I am confident this letter will provide current and prospective shareholders with a comprehensive overview of the new MedClean Technologies."

About MedClean Technologies, Inc.

MedClean Technologies, Inc. is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. MedClean's flagship MedClean(R) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. MedClean was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on MedClean can be found at http://www.medcleantechnologies.com and in filings with the Securities and Exchange Commission found at http://www.sec.gov.

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC on March 31, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

    Contacts:
    MedClean Technologies, Inc.               Investor Contact:
    Kevin Dunphy                              Cameron Donahue
    Chief Financial Officer                   Hayden IR
    (203) 798-1080                            (651) 653-1854
    kdunphy@medcleantechnologies.com          cameron@haydenir.com


'/>"/>
SOURCE MedClean Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MedClean Technologies Inc. Announces New Ticker Symbol
2. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
3. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
4. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
7. Advanced technologies aim to transform the coaching of top athletes
8. Global Med Technologies(R) Extends Its Worldwide Outreach
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
11. Neurobiological Technologies Reports Going Concern Qualification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... director. Mr. Still was selected through a careful months-long search by the RBMA Board ... to our members, has been a part of building the RBMA since 1992,” said ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of two biometric time and attendance tracking products: the new NCheck Cloud ... NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & Clients ... to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser ... $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a direct ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon ... this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Silicon Valley Hair ... to announce a new blog post about women’s hair loss. Although hair transplant procedures ... loss as they age. Menopause or genetics can be two reasons a woman may ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: